Singapore
AWAK Technologies and Singapore General Hospital launch pre-pivotal clinical trial of wearable peritoneal dialysis device
SINGAPORE, June 19, 2023 /PRNewswire/ -- AWAK Technologies (AWAK) and Singapore General Hospital (SGH) announce the launch of a pre-pivotal clinical trial with the enrolment of their first subject to study the safety and efficacy of an improved Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device.
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakima in Japan
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
Tessa Therapeutics’s ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma
SINGAPORE – June 16, 2023 – Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced promising safety and efficacy data from a study of its off-the-shelf CD30.CAR EBVST therapy (TT11X) in patients with relapsed or refractory (R/R) Hodgkin lymphoma.
Siemens to spend $2.2 bln to ramp up global production
SINGAPORE/ZURICH, June 15 (Reuters) - Siemens (SIEGn.DE) will spend 2 billion euros ($2.2 billion) on a new global investment plan, the German engineering group said on Thursday, to make its operations more resilient against supply chain disruptions and geopolitical tensions.
Late-breaking SCG101 Data Show 100% HBsAg+ Hepatocyte Eradication and 74.5% HCC Tumour Reduction With Single Dose HBsAg-specific TCR-T Cell Therapy
SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, presented late-breaking data from its first-in-class autologous HBsAg-specific T-Cell receptor-engineered T Cell (TCR-T) Therapy – SCG101 – at the International Society for Cell & Gene Therapy (ISCT) conference in Paris, France.
GENESIS MEDTECH NAMES INAUGURAL PRESIDENT TO DRIVE COMMERCIAL STRATEGY FOR NORTH AMERICA
SINGAPORE, MAY 15, 2023 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) is pleased to announce its appointment of Dr. Mark A. Turco (Dr. Turco), M.D., F.A.C.C., as President of Genesis MedTech Intervention, North America and CEO of JC Medical, Inc.
ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting
SAN MATEO, Calif. and SINGAPORE, May 15, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of new eblasakimab and farudodstat data in late-breaker oral and poster presentations respectively, at the 1st International Societies for Investigative Dermatology (ISID) meeting, which took place from May 10 to 13, 2023, in Tokyo, Japan.
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
SAN MATEO, Calif. and SINGAPORE, May 18, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has dosed the first patient in a Phase 2a proof-of-concept study of farudodstat, an oral dihydroorotate dehydrogenase (DHODH) inhibitor, in adult patients with severe alopecia areata (AA), an autoimmune condition causing hair loss
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
INGELHEIM, Germany & SINGAPORE--(BUSINESS WIRE)-- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers.
SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers
SINGAPORE & BOULDER, Colo., May 07, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a global leader in proteomics technology, today announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore.
